Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Histidine 386 and its role in cyclooxygenase and peroxidase catalysis by prostaglandin-endoperoxide H synthases.

Seibold SA, Ball T, Hsi LC, Mills DA, Abeysinghe RD, Micielli R, Rieke CJ, Cukier RI, Smith WL.

J Biol Chem. 2003 Nov 14;278(46):46163-70. Epub 2003 Sep 2.

2.

p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator.

Abeysinghe RD, Greene BT, Haynes R, Willingham MC, Turner J, Planalp RP, Brechbiel MW, Torti FM, Torti SV.

Carcinogenesis. 2001 Oct;22(10):1607-14.

PMID:
11576999
3.

The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload.

Farquharson MJ, Bagshaw AP, Porter JB, Abeysinghe RD.

Phys Med Biol. 2000 May;45(5):1387-96.

PMID:
10843111
4.

6-Alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labelling with indium.

Ellis BL, Sampson CB, Abeysinghe RD, Porter JB, Hider RC.

Eur J Nucl Med. 1999 Nov;26(11):1400-6.

PMID:
10552080
5.

Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S.

Blood. 1996 Jul 15;88(2):705-13.

6.

The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators.

Abeysinghe RD, Roberts PJ, Cooper CE, MacLean KH, Hider RC, Porter JB.

J Biol Chem. 1996 Apr 5;271(14):7965-72.

7.

Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes.

Abeysinghe RD, Ellis BL, Porter JB.

Eur J Nucl Med. 1994 Oct;21(10):1141-7.

PMID:
7828625
8.

Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.

Porter JB, Singh S, Hoyes KP, Epemolu O, Abeysinghe RD, Hider RC.

Adv Exp Med Biol. 1994;356:361-70. Review. No abstract available.

PMID:
7887242
9.

Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.

Porter JB, Abeysinghe RD, Hoyes KP, Barra C, Huehns ER, Brooks PN, Blackwell MP, Araneta M, Brittenham G, Singh S, et al.

Br J Haematol. 1993 Sep;85(1):159-68.

PMID:
8251385
10.

Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.

Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S.

Drug Metab Dispos. 1993 Jul-Aug;21(4):640-4.

PMID:
8104123
11.

In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.

Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB.

Exp Hematol. 1993 Jan;21(1):86-92.

PMID:
8417963
12.

Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.

Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC.

Blood. 1991 Nov 15;78(10):2727-34.

13.

Secretion of neutrophil secondary granules occurs during granulocyte-macrophage colony stimulating factor induced margination.

Devereux S, Porter JB, Hoyes KP, Abeysinghe RD, Saib R, Linch DC.

Br J Haematol. 1990 Jan;74(1):17-23.

PMID:
2178671

Supplemental Content

Loading ...
Support Center